Page 195 - 2019_04-Haematologica-web

Anti-β2GPI-D5 are not thrombogenic in animals
Figure 3. Deposition of β2glycoprotein I (β2GPI), human IgG and C3 on mesenteric vessels of rats treated with antibodies to domain 5 (D5) or domain 1 (D1) of β2GPI. The animals were treated with lipopolysaccharide (LPS) followed by the injection of antibodies directed against domain 5 (D5), domain 1 (D1), or negative for anti-β2GPI (NHS). Mesenteric tissue samples after 90 minutes analyzed for vascular deposition of β2GPI, human IgG and C3 by immunofluorescence. Original mag- nification 200x. Scale bar 50 mm.
Figure 4. Anti-domain 5 (D5) antibodies fail to interact with β2glycoprotein I (β2GPI) bound to cardiolipin (CL). Reactivity of anti-D5 (aD5) ( ), anti-domain 1 (aD1) ( ) or anti-β2GPI negative (NHS) ( ) antibodies (50 mg/mL) against different concentrations of β2GPI bound to cardiolipin. Binding of IgG to: (A) CL alone, (B) 1 mg/mL CL-bound β2GPI, (C) 5 mg/mL CL-bound β2GPI, (D) 75 mg/mL CL-bound β2GPI. Optical Density (OD) values are expressed as median and interquartile range, and presented as box plots. *P<0.05.
AB
CD
haematologica | 2019; 104(4)
823